Jody C Chuang, MD
Hematology/Oncology · Santa Clara
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 4
- 1 carrier
- Office
- 1
Offices
1 location · Permanente Medical Group Inc · 10,928 clinicians in this group
Plans that list them
4 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chuang’s office at (408) 851-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Kaiser Permanente Dual Complete North P2 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Dual Complete North P23 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Basic Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Enhanced Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
California Medical Board record
Licence A117882 · Current
Licensed to practise in California · since 2011 · expires 2027-01-31 · University of Southern California Keck School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Drugs they prescribed that Part D paid
$4,003,024
Pharmacies billed $4,003,024 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 7% of their Part D prescriptions (43 of 655) in 2024. Above the middle of the specialty; the typical hematology-oncology clinician is at 5%.
400 generic and 255 brand-name prescriptions · $4,003,024 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Tagrisso | 116 | $2,004,222 | $17,278 |
| Alecensa | 25 | $501,035 | $20,041 |
| Ibrance | 32 | $494,317 | $15,447 |
| Lorbrena | 20 | $372,850 | $18,643 |
| Xalkori | 14 | $289,245 | $20,660 |
See all 13 drugs
| Tagrisso | 116 | $2,004,222 | $17,278 |
| Alecensa | 25 | $501,035 | $20,041 |
| Ibrance | 32 | $494,317 | $15,447 |
| Lorbrena | 20 | $372,850 | $18,643 |
| Xalkori | 14 | $289,245 | $20,660 |
| Gilotrif | 12 | $153,794 | $12,816 |
| Anastrozole | 168 | $4,971 | $30 |
| Exemestane | 13 | $879 | $68 |
| Hydrocodone-Acetaminophen | 22 | $706 | $32 |
| Letrozole | 31 | $631 | $20 |
| Tamoxifen Citrate | 16 | $402 | $25 |
| Albuterol Sulfate Hfa | 13 | $267 | $21 |
| Oxycodone | 11 | $260 | $24 |
Year by year
| 2024 | 655 | 150 | 7% (43) | 39% | $4,003,024 |
| 2023 | 631 | 123 | 6% (35) | 42% | $3,965,306 |
| 2022 | 537 | 109 | 3% (17) | 36% | $2,972,815 |
| 2021 | 558 | 114 | 7% (38) | 34% | $2,848,002 |
| 2020 | 505 | 100 | 7% (33) | 38% | $2,173,867 |
| 2019 | 435 | 88 | 4% (18) | 38% | $1,788,867 |
| 2018 | 468 | 95 | 10% (45) | 24% | $1,097,714 |
| 2017 | 29 | 14 | None | None | $17,462 |
| 2014 | 56 | 18 | 34% (19) | None | $1,322 |
| 2013 | 104 | 14 | None | None | $2,768 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Tagrisso | 116 | $1,938,009 | $16,707 |
| Ibrance | 55 | $770,512 | $14,009 |
| Alecensa | 20 | $466,641 | $23,332 |
| Gilotrif | 20 | $254,759 | $12,738 |
| Anastrozole | 145 | $4,089 | $28 |
| Letrozole | 32 | $577 | $18 |
| Morphine Sulfate Er | 16 | $392 | $25 |
| Hydrocodone-Acetaminophen | 12 | $155 | $13 |
2022: 9 drugs
| Tagrisso | 86 | $1,572,082 | $18,280 |
| Ibrance | 48 | $629,931 | $13,124 |
| Alecensa | 21 | $415,299 | $19,776 |
| Anastrozole | 148 | $3,958 | $27 |
| Exemestane | 14 | $940 | $67 |
| Tamoxifen Citrate | 14 | $742 | $53 |
| Letrozole | 34 | $697 | $21 |
| Imatinib Mesylate | 12 | $643 | $54 |
| Mirtazapine | 12 | $206 | $17 |
2021: 12 drugs
| Tagrisso | 84 | $1,532,059 | $18,239 |
| Ibrance | 43 | $527,893 | $12,277 |
| Alecensa | 24 | $414,232 | $17,260 |
| Spiriva Respimat | 12 | $5,150 | $429 |
| Anastrozole | 122 | $3,121 | $26 |
| Imatinib Mesylate | 12 | $1,821 | $152 |
| Exemestane | 29 | $1,576 | $54 |
| Tamoxifen Citrate | 18 | $996 | $55 |
| Letrozole | 28 | $686 | $25 |
| Hydrocodone-Acetaminophen | 19 | $396 | $21 |
| Mirtazapine | 11 | $223 | $20 |
| Oxycodone | 11 | $154 | $14 |
2020: 11 drugs
| Tagrisso | 68 | $1,100,454 | $16,183 |
| Alecensa | 26 | $436,753 | $16,798 |
| Ibrance | 32 | $401,946 | $12,561 |
| Spiriva Respimat | 14 | $4,998 | $357 |
| Anastrozole | 124 | $3,094 | $25 |
| Exemestane | 14 | $1,532 | $109 |
| Tamoxifen Citrate | 15 | $791 | $53 |
| Diphenoxylate-Atropine | 18 | $533 | $30 |
| Hydrocodone-Acetaminophen | 26 | $513 | $20 |
| Letrozole | 19 | $467 | $25 |
| Lorazepam | 11 | $78 | $7 |
2019: 12 drugs
| Tagrisso | 53 | $818,910 | $15,451 |
| Ibrance | 34 | $437,226 | $12,860 |
| Alecensa | 21 | $336,329 | $16,016 |
| Gilotrif | 17 | $162,774 | $9,575 |
| Spiriva Respimat | 20 | $5,144 | $257 |
| Anastrozole | 103 | $2,524 | $25 |
| Tamoxifen Citrate | 16 | $843 | $53 |
| Letrozole | 20 | $401 | $20 |
| Levothyroxine | 11 | $261 | $24 |
| Gabapentin | 11 | $250 | $23 |
| Hydrocodone-Acetaminophen | 12 | $189 | $16 |
| Ondansetron | 13 | $130 | $10 |
2018: 11 drugs
| Tagrisso | 38 | $555,145 | $14,609 |
| Alecensa | 14 | $221,689 | $15,835 |
| Akynzeo | 20 | $29,921 | $1,496 |
| Dexamethasone | 49 | $1,867 | $38 |
| Anastrozole | 52 | $1,370 | $26 |
| Prochlorperazine Maleate | 48 | $517 | $11 |
| Ondansetron | 24 | $396 | $17 |
| Hydrocodone-Acetaminophen | 21 | $288 | $14 |
| Levothyroxine | 16 | $231 | $14 |
| Lidocaine Hcl Viscous | 13 | $179 | $14 |
| Famotidine | 13 | $127 | $10 |
2014: 1 drug
| Metformin | 11 | $106 | $10 |
Professional record
- NPI
- 1508147083
- Licence
- CA A117882California A117882: Current · expires 2027-01-31
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 2020 Zonal Ave Ste Ird620, Los Angeles, CA, 90089
- NPI first listed
- 2011-08-29
- NPI last updated
- 2021-12-17
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.